The present invention encompasses the surprising finding that nanoparticle compositions can have beneficial effects on allergy even when prepared without a known specific allergy therapeutic. The present invention provides such nanoparticle compositions. In some embodiments, provided nanoparticles a
The present invention encompasses the surprising finding that nanoparticle compositions can have beneficial effects on allergy even when prepared without a known specific allergy therapeutic. The present invention provides such nanoparticle compositions. In some embodiments, provided nanoparticles are associated with functional elements that cause the nanoparticles to mimic bacterial cells. The present invention encompasses the surprising finding that provided nanoparticles may be useful for treatment and/or prevention of multiple different allergies in a single patient. The present invention encompasses the recognition that provided empty nanoparticles may be useful as a “pan-allergy” therapeutic and/or vaccine.
대표청구항▼
1. A method of treating allergy, the method comprising: administering a pharmaceutical composition to a subject suffering from or susceptible to allergic reaction to a particular allergen, such that at least one of the subject's symptoms of allergy are reduced or delayed, wherein:(i) the pharmaceuti
1. A method of treating allergy, the method comprising: administering a pharmaceutical composition to a subject suffering from or susceptible to allergic reaction to a particular allergen, such that at least one of the subject's symptoms of allergy are reduced or delayed, wherein:(i) the pharmaceutical composition comprises a population of nanoparticles formed from at least one polymer, which nanoparticles comprise at least one microbial mimic entity,wherein the at least one microbial mimic entity is a pathogen-associated molecular pattern (PAMP);(ii) the pharmaceutical composition is substantially free of the particular allergen; and(iii) the pharmaceutical composition is formulated for delivery to the subject, andwherein the administering does not also comprise administering the particular allergen. 2. The method of claim 1, wherein the step of administering is performed via a mode of administration selected from the group consisting of oral (PO), intravenous (IV), intramuscular (IM), intra-arterial, intramedullary, intrathecal, subcutaneous (SQ), intraventricular, transdermal, interdermal, intradermal, rectal (PR), vaginal, intraperitoneal (IP), intragastric (IG), topical, transdermal, mucosal, intranasal, buccal, enteral, vitreal, sublingual administration, by intratracheal instillation, by bronchial instillation, and by inhalation. 3. The method of claim 1, wherein the step of administering comprises administering multiple individual doses to the subject over a specified period of time. 4. The method of claim 1, wherein the at least one polymer is PLGA. 5. The method of claim 1, wherein the PAMP comprises at least one entity associated with an outer surface of a bacterial cell. 6. The method of claim 5, wherein the at least one entity associated with the outer surface of a bacterial cell is selected from the group consisting of: bacterial lipopolysaccharide, bacterial flagellin, lipoteichoic acid from gram positive bacteria, diacyllipopeptides, triacyllipopeptides, lipopeptide Pam3CysSK4, zymosan from yeast cell wall, peptidoglycans, double-stranded RNAs, unmethylated CpG motifs, heat shock proteins, taxol, viral double-stranded RNA, viral single-stranded RNA, double-stranded DNA, haemozoin, characteristic portions thereof, and/or combinations thereof. 7. The method of claim 5, wherein the at least one entity associated with the outer surface of a bacterial cell is selected from the group consisting of: bacterial lipopolysaccharide, bacterial flagellin, lipoteichoic acid from gram positive bacteria, peptidoglycan, double-stranded RNAs, unmethylated CpG motifs, any TLR ligands listed in Table 1, characteristic portions thereof, and/or combinations thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (99)
Eberle Marcel K. (Riehen CHX), 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8cyclosporins.
Sinclair Peter J. (Highland Park NJ) Organ Helen M. (Roselle Park NJ) Wyvratt Matthew J. (Mountainside NJ), Amino O-aryl macrolides having immunosuppressive activity.
Ok Hyun O. (Edison NJ) Beattie Thomas R. (Scotch Plains NJ) Fisher Michael H. (Ringoes NJ) Wyvratt Matthew J. (Mountainside NJ) Goulet Mark (Westfield NJ), Aminomacrolides and derivatives having immunosuppressive activity.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Molnar-Kimber Katherine L. (Glenside PA) Ocain Timothy D. (Waltham MA) Vernon Steven K. (Havertown PA) Huang John J. (San Carlos CA), Biotin esters of rapamycin.
Goulet Mark (Westfield NJ) Beattie Thomas R. (Scotch Plains NJ) Wyvratt Matthew J. (Mountainside NJ), Fluoromacrolides having immunosuppressive activity.
Patchett Arthur A. (Westfield NJ) Taub David (Metuchen NJ) Goegelman Robert T. (Linden NJ), Immunosuppressive cyclosporin analogs with modified amino acids at position-8.
Durette Philippe L. (New Providence NJ) Pessolano Arsenio A. (Colonia NJ) Kollonitsch Janos (Westfield NJ), Immunosuppressive fluorinated cyclosporin analogs.
Mohr Judy M. (Menlo Park CA) Baker Richard W. (Palo Alto CA) Nakaji Lisa A. (San Jose CA), Liquid reservoir transdermal patch for the administration of ketorolac.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Ok Hyun O. (Edison NJ) Goulet Joung (Westfield NJ) Sinclair Peter J. (Highland Park NJ), N-heteroaryl, N-alkylheteroaryl, N-alkenylheteroaryl and N-alkynylheteroarylmacrolides having immunosuppressive activity.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Burks, Jr.,A. Wesley; Bannon,Gary A.; Sampson,Hugh A.; Helm,Ricki M.; Stanley,J. Steven; Rabjohn,Patrick A., Nucleic acids encoding ara h 3 polypeptides.
Goulet Mark (Westfield NJ) Organ Helen M. (Fanwood NJ) Parsons William H. (Edison NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity.
Goulet Mark (Westfield NJ) Wong Frederick (Glen Ridge NJ) Sinclair Peter J. (Highland Park NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity.
Goulet Mark (Westfield NJ) Parsons William H. (Edison NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives.
Goulet Mark (Westfield NJ) Parsons William H. (Edison NJ) Organ Helen M. (Fanwood NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity.
A. Wesley Burks, Jr. ; J. Steven Stanley ; Gael Cockrell ; Nina E. King ; Hugh A. Sampson ; Ricki M. Helm ; Gary A. Bannon, Peanut allergens and methods.
Okuhara Masakuni (Ibaraki JPX) Tanaka Hirokazu (Ibaraki JPX) Goto Toshio (Ibaraki JPX) Kino Tohru (Tsuchiura JPX) Hatanaka Hiroshi (Ibaraki JPX), Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same.
Okuhara Masakuni (Ibaraki JPX) Tanaka Hirokazu (Ibaraki JPX) Goto Toshio (Ibaraki JPX) Kino Tohru (Tsuchiura JPX) Hatanaka Hiroshi (Ibaraki JPX), Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same.
Okuhara Masakuni (Sakuramura JPX) Tanaka Hirokazu (Sakuramura JPX) Goto Toshio (Sakuramura JPX) Kino Tohru (Tsuchiura JPX) Hatanaka Hiroshi (Sakuramura JPX), Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.